SEC Form 4 · accession 0001209191-19-004549
NovoCure Ltd · NVCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eilon D. Kirson
Officer — Chief Science Officer
Period of report
Jan 16, 2019
Accepted (ET)
Jan 18, 2019 · 4:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645113
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Jan 16, 2019 | M | 100,000 | $14.37 | A | 209,063 | D | |
| Ordinary SharesF2 | Jan 16, 2019 | S | 100,000 | $45.11 | D | 109,063 | D | |
| Ordinary SharesF1 | Jan 17, 2019 | M | 68,813 | $14.37 | A | 177,876 | D | |
| Ordinary SharesF3 | Jan 17, 2019 | S | 68,813 | $45.25 | D | 109,063 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Buy Ordinary SharesF4 | $14.37 | Jan 16, 2019 | M | 100,000 | D | — | Feb 23, 2025 | Ordinary Shares | 100,000 | 135,335 | D |
| Options to Buy Ordinary SharesF4 | $14.37 | Jan 17, 2019 | M | 68,813 | D | — | Feb 23, 2025 | Ordinary Shares | 68,813 | 66,522 | D |
Explanation of responses
- F1Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson.
- F2On January 16, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson, Mr. Kirson sold 100,000 shares in multiple trades at prices ranging from $45.00 to $45.36. The price reported above reflects the weighted average sale price. Mr. Kirson hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- F3On January 17, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson, Mr. Kirson sold 68,813 shares in multiple trades at prices ranging from $45.00 to $45.66. The price reported above reflects the weighted average sale price. Mr. Kirson hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- F4Fully vested and currently exercisable as of the date hereof.